IL160845A0 - Linked biaryl compounds - Google Patents
Linked biaryl compoundsInfo
- Publication number
- IL160845A0 IL160845A0 IL16084502A IL16084502A IL160845A0 IL 160845 A0 IL160845 A0 IL 160845A0 IL 16084502 A IL16084502 A IL 16084502A IL 16084502 A IL16084502 A IL 16084502A IL 160845 A0 IL160845 A0 IL 160845A0
- Authority
- IL
- Israel
- Prior art keywords
- biaryl compounds
- linked biaryl
- linked
- compounds
- biaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32255601P | 2001-09-14 | 2001-09-14 | |
US33543401P | 2001-11-30 | 2001-11-30 | |
US37862702P | 2002-05-07 | 2002-05-07 | |
US38683302P | 2002-06-06 | 2002-06-06 | |
PCT/US2002/029232 WO2003024395A2 (en) | 2001-09-14 | 2002-09-13 | Linked biaryl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160845A0 true IL160845A0 (en) | 2004-08-31 |
Family
ID=27502245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16084502A IL160845A0 (en) | 2001-09-14 | 2002-09-13 | Linked biaryl compounds |
Country Status (13)
Country | Link |
---|---|
US (2) | US6869975B2 (ko) |
EP (1) | EP1435946B8 (ko) |
JP (1) | JP4269052B2 (ko) |
KR (1) | KR20040063897A (ko) |
CN (1) | CN1585638A (ko) |
AU (1) | AU2002336532C1 (ko) |
BR (1) | BR0212512A (ko) |
CA (1) | CA2460313C (ko) |
ES (1) | ES2443642T3 (ko) |
IL (1) | IL160845A0 (ko) |
MX (1) | MXPA04002330A (ko) |
NZ (1) | NZ531917A (ko) |
WO (1) | WO2003024395A2 (ko) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
JP4269052B2 (ja) | 2001-09-14 | 2009-05-27 | アムジエン・インコーポレーテツド | 連結ビアリール化合物 |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
CA2521175A1 (en) * | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
WO2005012221A1 (ja) * | 2003-08-04 | 2005-02-10 | Ono Pharmaceutical Co., Ltd. | ジフェニルエーテル化合物、その製造方法および用途 |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US7968723B2 (en) * | 2004-05-05 | 2011-06-28 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
DE602005022585D1 (de) * | 2004-05-05 | 2010-09-09 | High Point Pharmaceuticals Llc | Phenoxyessigsäurederivate als ppar-agonisten |
US8053598B2 (en) * | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
DE602005020313D1 (de) * | 2004-08-12 | 2010-05-12 | Amgen Inc | Bisaryl-sulfonamide |
EP1650183A1 (en) * | 2004-10-21 | 2006-04-26 | Cellzome Ag | (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy |
AU2005311826A1 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as PPAR active compounds |
JP2008521829A (ja) * | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
CA2594860A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
FR2880886B1 (fr) * | 2005-01-14 | 2007-04-06 | Merck Sante Soc Par Actions Si | Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
EP1843734A4 (en) | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
DE102005020230A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
DE102005020229A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
WO2006132928A2 (en) * | 2005-06-03 | 2006-12-14 | Case Western Reserve University | Methods and compositions for treating inflammation |
EP2298742B1 (en) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy acetic acids as PPAR delta activators |
EP1911738A4 (en) * | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | PHENOXYALKANSÄUREVERBINDUNG |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
EP1931658A2 (en) * | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
AU2006287513A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1, 3-disubstituted indole derivatives for use as PPAR modulators |
BRPI0615948A2 (pt) * | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma Inc | ácidos fenóxi acéticos como ativadores de ppar delta |
TW200730474A (en) | 2005-12-29 | 2007-08-16 | Schering Ag | Diamine derivatives as inhibitors of leukotriene A4 hydrolease |
CA2645719A1 (en) * | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
WO2008147445A2 (en) * | 2006-11-09 | 2008-12-04 | University Of Maryland, Baltimore | Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent |
PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
CA2708391A1 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
CN102014897B (zh) | 2008-04-21 | 2015-08-05 | 西格纳姆生物科学公司 | 化合物、组合物和其制备方法 |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2782085A1 (en) * | 2010-01-06 | 2011-07-14 | Panmira Pharmaceuticals, Llc | Dp2 antagonist and uses thereof |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
JP6527851B2 (ja) | 2013-03-12 | 2019-06-05 | セルタクシス,インコーポレイテッド | ロイコトリエンa4加水分解酵素を阻害する方法 |
AU2014239567B2 (en) | 2013-03-14 | 2017-12-14 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014152229A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CA3102077A1 (en) | 2018-05-31 | 2019-12-05 | Sanjeev AHUJA | Method of reducing pulmonary exacerbations in respiratory disease patients |
KR20230054373A (ko) | 2020-07-22 | 2023-04-24 | 르네오 파마슈티컬스, 인크. | 결정질 ppar-델타 작용제 |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3038934A (en) * | 1959-03-17 | 1962-06-12 | Smith Kline French Lab | Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids |
US4443536A (en) * | 1981-08-25 | 1984-04-17 | Eastman Kodak Company | Nondiffusible photographic couplers and photographic elements and processes employing same |
US4466902A (en) * | 1982-01-31 | 1984-08-21 | Ipposha Oil Industries, Co., Ltd. | Rust inhibitor |
EP0359169B1 (en) * | 1988-09-14 | 1995-07-26 | Eastman Kodak Company | Photographic recording material comprising magenta coupler and a chalcogenazolium salt |
JPH10502256A (ja) | 1994-07-01 | 1998-03-03 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物のペルオキシソーム増殖物質活性化受容体およびその使用 |
WO1997028137A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
JP2002503202A (ja) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
AU719146B2 (en) | 1996-02-02 | 2000-05-04 | Merck & Co., Inc. | Antidiabetic agents |
US6090839A (en) | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
EP0978506B1 (en) * | 1997-03-27 | 2003-01-08 | Taisho Pharmaceutical Co., Ltd | 2-phenoxyaniline derivatives |
DE69840510D1 (de) | 1997-07-24 | 2009-03-12 | Astellas Pharma Inc | Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung |
EP1056751A4 (en) | 1997-12-23 | 2003-01-22 | Commw Scient Ind Res Org | BORIC COMPOUNDS |
EP1053227B1 (en) | 1998-01-29 | 2008-11-05 | Amgen Inc. | Ppar-gamma modulators |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
DE69920923T2 (de) * | 1998-07-24 | 2005-10-20 | Teijin Ltd. | Anthranilsäurederivate |
US6525094B1 (en) | 1999-06-01 | 2003-02-25 | The University Of Texas Southwestern Medical Center | Method of treating hair loss using diphenylether derivatives |
CA2376919C (en) | 1999-06-18 | 2008-11-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
NZ516455A (en) | 1999-06-30 | 2004-03-26 | Tularik Inc | Compounds for the modulation of PPARgamma activity |
US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
AU7115300A (en) | 1999-09-08 | 2001-04-10 | Glaxo Group Limited | Oxazole ppar antagonists |
JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
KR100771286B1 (ko) | 2000-06-28 | 2007-10-29 | 암젠 인크 | 퀴놀리닐 및 벤조티아졸릴 ppar-감마 조절물질 |
EP1305285B1 (en) | 2000-07-25 | 2007-05-16 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
JP4790969B2 (ja) | 2000-08-11 | 2011-10-12 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
GB0024362D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
WO2002070011A2 (en) | 2001-02-02 | 2002-09-12 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
CA2438480C (en) * | 2001-02-14 | 2011-05-03 | Abbott Laboratories | Glucocorticoid receptor modulators |
US6777442B2 (en) * | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
US7078422B2 (en) | 2001-03-23 | 2006-07-18 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
WO2003018515A2 (en) * | 2001-08-24 | 2003-03-06 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
JP4269052B2 (ja) | 2001-09-14 | 2009-05-27 | アムジエン・インコーポレーテツド | 連結ビアリール化合物 |
DK1431284T3 (da) * | 2001-09-27 | 2008-02-18 | Kyorin Seiyaku Kk | Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel |
US7230031B2 (en) * | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
-
2002
- 2002-09-13 JP JP2003528493A patent/JP4269052B2/ja not_active Expired - Fee Related
- 2002-09-13 AU AU2002336532A patent/AU2002336532C1/en not_active Ceased
- 2002-09-13 US US10/244,063 patent/US6869975B2/en not_active Expired - Fee Related
- 2002-09-13 CA CA2460313A patent/CA2460313C/en not_active Expired - Fee Related
- 2002-09-13 WO PCT/US2002/029232 patent/WO2003024395A2/en active IP Right Grant
- 2002-09-13 BR BR0212512-9A patent/BR0212512A/pt not_active IP Right Cessation
- 2002-09-13 CN CNA028223241A patent/CN1585638A/zh active Pending
- 2002-09-13 MX MXPA04002330A patent/MXPA04002330A/es active IP Right Grant
- 2002-09-13 KR KR10-2004-7003851A patent/KR20040063897A/ko not_active Application Discontinuation
- 2002-09-13 ES ES02773386.4T patent/ES2443642T3/es not_active Expired - Lifetime
- 2002-09-13 IL IL16084502A patent/IL160845A0/xx unknown
- 2002-09-13 NZ NZ531917A patent/NZ531917A/en unknown
- 2002-09-13 EP EP02773386.4A patent/EP1435946B8/en not_active Expired - Lifetime
-
2004
- 2004-08-20 US US10/939,918 patent/US7645779B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1435946A2 (en) | 2004-07-14 |
US20080161351A1 (en) | 2008-07-03 |
WO2003024395A8 (en) | 2004-01-22 |
CN1585638A (zh) | 2005-02-23 |
WO2003024395A3 (en) | 2003-12-11 |
US6869975B2 (en) | 2005-03-22 |
WO2003024395A2 (en) | 2003-03-27 |
EP1435946B1 (en) | 2013-11-06 |
MXPA04002330A (es) | 2005-04-08 |
AU2002336532B2 (en) | 2007-10-18 |
JP2005508318A (ja) | 2005-03-31 |
BR0212512A (pt) | 2004-10-26 |
EP1435946A4 (en) | 2006-02-01 |
JP4269052B2 (ja) | 2009-05-27 |
EP1435946B8 (en) | 2013-12-18 |
CA2460313C (en) | 2011-03-08 |
NZ531917A (en) | 2006-01-27 |
ES2443642T3 (es) | 2014-02-20 |
KR20040063897A (ko) | 2004-07-14 |
AU2002336532C1 (en) | 2008-10-16 |
CA2460313A1 (en) | 2003-03-27 |
US20030149108A1 (en) | 2003-08-07 |
US7645779B2 (en) | 2010-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160845A0 (en) | Linked biaryl compounds | |
AU2002349297A8 (en) | Statin-like compounds | |
GB0101996D0 (en) | Organtic compounds | |
GB0112324D0 (en) | Compounds | |
GB0102668D0 (en) | Compounds | |
GB0108475D0 (en) | New compounds | |
GB0108102D0 (en) | Compounds | |
GB0102673D0 (en) | Compounds | |
GB0119474D0 (en) | Compounds | |
GB0102665D0 (en) | Compounds | |
GB0119472D0 (en) | Compounds | |
EP1458669A4 (en) | ACTIVE COMPOUNDS ON THE NEUROLOGICAL PLAN | |
GB0115178D0 (en) | Compounds | |
GB0118364D0 (en) | Compounds | |
GB0119473D0 (en) | Compounds | |
GB0108097D0 (en) | Compounds | |
GB0105098D0 (en) | Compounds | |
HUP0102279D0 (en) | New compounds | |
GB0117780D0 (en) | New compounds | |
GB0104399D0 (en) | Compounds | |
GB0118994D0 (en) | Compounds | |
GB0104397D0 (en) | Compounds | |
GB0103314D0 (en) | Compounds | |
GB0104401D0 (en) | Compounds | |
GB0102670D0 (en) | Compounds |